Focusing on core patient-reported outcomes in cancer clinical trials - Letter

Clinical Cancer Research

Volumn 22, Issue 22, 2016, Pages 5617-

  Groenvold, Mogens ^a,b   Aaronson, Neil K ^c   Darlington, Anne Sophie E ^d   Fitzsimmons, Deborah ^e   Greimel, Eva ^f   Holzner, Bernhard ^g   Reijneveld, Jaap C ^h   Tomaszewski, Krzysztof A ⁱ   Verdonck De Leeuw, Irma ^h   Van De Poll Franse, Lonneke ^c  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e SWANSEA UNIVERSITY   (United Kingdom)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; HUMAN; LETTER; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT-REPORTED OUTCOME; PERSONAL EXPERIENCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE ASSESSMENT; SOCIAL INTERACTION; BIOASSAY; CLINICAL TRIAL (TOPIC); METHODOLOGY; NEOPLASM; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; PATIENT REPORTED OUTCOME MEASURES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84995948135     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1529     Document Type: Letter

References (5)

1. Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and diseaserelated symptoms. Clin Cancer Res 2016;22:1553-8.
2. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PROCTCAE). J Natl Cancer Inst 2014;106:1-11.
3. Petersen MA, Groenvold M, Aaronson NK, Chie WC, Conroy T, Costantini A, et al. Development of computerized adaptive testing (CAT) for the EORTC QLQ-C30 physical functioning dimension. Qual Life Res 2011;20:479-90.
4. Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 2014;106:pii:dju129.
5. European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: the use of patient-reported outcome (PRO) measures in oncology studies. London, United Kingdom: European Medicines Agency; 2016. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Other/2016/04/WC500205159.pdf.